Bibliographic Details
| Title: |
Imprimis (C) |
| Authors: |
Elterman, Karen, Appel, Marc, Casadesus-Masanell, Ramon |
| Source: |
Harvard Business School Cases. Apr 01, 2017, p1. 7p. |
| Abstract: |
This case is a supplement to Imprimis (Case A) and Imprimis (Case B). Set in 2015, it first describes Imprimis's decision to introduce its own line of compounded eye drop medication called LessDrops. The case then examines the moral dilemma faced by CEO Mark Baum, who was struck by the problem of high drug prices in the United States. Recent, drastic price hikes on pharmaceutical drugs, such as those initiated by Turing Pharmaceuticals under CEO Martin Shkreli, had recently brought media attention to this issue. Baum believed it would be relatively easy for Imprimis to create compounded versions of many of the affected drugs, which could increase competition in the pharmaceutical industry and lessen the strain both on patients and the healthcare system as a whole. However, doing so would require the company to raise capital, strengthen its sales force, and increase its manufacturing capabilities. The decision was further complicated by the relatively low barrier to entry, and by the ubiquitous nature of the drug pricing problem. Baum had to decide whether Imprimis should stick with its already-successful ophthalmology business, or begin the endeavor of combatting high drug prices, going up against powerful competitors in the drug industry. . [ABSTRACT FROM AUTHOR] |
|
Copyright © Harvard Business Publishing. All Rights Reserved. This content is intended for individual research use only, subject to the following: Unless permission is expressly granted in a separate license, this content may NOT be used for classroom or teaching use, which includes teaching materials, electronic reserves, course packs or persistent linking from syllabi. Please consult your institution's librarian about the nature of relevant licenses held by your institution and the restrictions that may or may not apply.Unless permission is expressly granted in a separate license, this content may NOT be used in corporate training and/or as corporate learning materials. For corporate users, please consult the specific terms of your company's license(s) for complete information and restrictions. For more information and teaching resources from Harvard Business Publishing including Harvard Business School Cases, eLearning products, and business simulations please visit hbsp.harvard.edu. (Copyright applies to all Abstracts.) |
| URL: |
http://hbr.org/product/a/an/717497-PDF-ENG |
| Database: |
Business Source Complete |
